Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | CPT1A | P50416 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | PRPS1 | P60891 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | MYC | P01106 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13619970 | 0.90 | KMT2A (0.44) | PTGDR2HTTCNR2CNR1MYC | |
| SCHEMBL2644030 | 0.86 | CPT1A (0.44) | PTGDR2CPT1ACNR2CNR1KCNA3 | |
| SCHEMBL2643415 | 0.85 | IDO1 (0.47) | HTTCNR2CNR1PRPS1AVPR1A | |
| SCHEMBL2642993 | 0.85 | CNR2 (0.48) | CPT1ACNR2CNR1PRPS1MCL1 | |
| SCHEMBL2642659 | 0.83 | CNR2 (0.51) | CNR2CNR1PRPS1ALDH1A1 | |
| SCHEMBL13619973 | 0.82 | HPGD (0.50) | CNR2CNR1HTR6ALDH1A1MAPT | |
| SCHEMBL2642676 | 0.82 | KDM4E (0.48) | CPT1AHTTCNR2CNR1CA1 | |
| SCHEMBL2643380 | 0.82 | CNR2 (0.56) | CNR2CNR1 | |
| SCHEMBL3098967 | 0.82 | HTR6 (0.59) | CPT1ACNR2CNR1PRPS1MCL1 | |
| SCHEMBL1127285 | 0.81 | PLK1 (0.57) | CNR2CNR1PLK1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100348596-C | Indole-3-carboxamides as glucokinase (GK) activators | HOFFMANN LA ROCHE (CH) | 2007-11-14 | — | — | CN | disclosed |
| EP-1549638-B1 | INDOLE-3-CARBOXAMIDES AS GLUCOKINASE (GK) ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2007-10-03 | — | — | EP | disclosed |
| CN-1688574-A | Indole-3-carboxamides as glucokinase (GK) activators | HOFFMANN LA ROCHE (CH) | 2005-10-26 | — | — | CN | disclosed |
| EP-1549638-A1 | INDOLE-3-CARBOXAMIDES AS GLUCOKINASE (GK) ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-06 | — | — | EP | disclosed |
| US-6881844-B2 | Indole-3-carboxamides as glucokinase activators | HOFFMAN-LA ROCHE INC. (US) | 2005-04-19 | — | — | US | disclosed |
| WO-2004031179-A1 | INDOLE-3-CARBOXAMIDES AS GLUCOKINASE (GK) ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-15 | — | — | WO | disclosed |
| US-20040067939-A1 | Indole-3-carboxamides as glucokinase activators | CORBETT WENDY LEA (US) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067939-A1 | Indole-3-carboxamides as glucokinase activators | GCKR, GPR119, GCK | PTGDR2 2084/4885CPT1A 111/4885HTT 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.